Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 9/20 | 0.43 |
| ▸ | HTR6 | P50406 | 5/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 2/20 | 0.36 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7468698 | 0.87 | HTR6 (0.41) | GHSRHTR6AKR1B1CES1PDE7A | |
| SCHEMBL121113 | 0.81 | GHSR (0.43) | GHSRHTR6AKR1B1PDE7AIDO1 | |
| SCHEMBL4590370 | 0.77 | AKR1B1 (0.36) | HTR6AKR1B1CES1PDE7A | |
| SCHEMBL3459900 | 0.76 | HTR6 (0.55) | GHSRHTR6 | |
| SCHEMBL7471467 | 0.76 | MAPT (0.50) | HTR6AKR1B1PDE7AIDO1 | |
| SCHEMBL125321 | 0.69 | GHSR (0.66) | GHSR | |
| SCHEMBL5345525 | 0.69 | AKR1C3 (0.47) | HTR6AKR1B1PDE7AIDO1 | |
| SCHEMBL7471179 | 0.68 | BRD4 (0.47) | GHSRHTR6AKR1B1PDE7A | |
| SCHEMBL5344885 | 0.67 | AHR (0.46) | AKR1B1CES1PDE7AIDO1CMA1 | |
| SCHEMBL128576 | 0.67 | BRD4 (0.56) | GHSRHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103443076-B | Indol-2-one derivatives disubstituted in position 3, their preparation and their therapeutic application | 赛诺菲-安万特 | 2016-06-22 | — | — | CN | disclosed |
| CN-103443076-A | Indol-2-one derivatives disubstituted in position 3, their preparation and their therapeutic application | SANOFI AVENTIS | 2013-12-11 | — | — | CN | disclosed |
| US-8202871-B2 | Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2012-06-19 | — | — | US | disclosed |
| EP-2188253-B1 | Indol-2-one derivatives disubstituted in 3-position, preparation thereof and therapeutic use thereof | SANOFI SA (FR) | 2012-03-07 | — | — | EP | disclosed |
| US-20110118280-A1 | INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-05-19 | — | — | US | disclosed |
| US-20100210662-A1 | INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-08-19 | — | — | US | disclosed |
| EP-2188253-A2 | INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009056707-A2 | INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210662-A1 | INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | IDO2, IDO1, TPH2 | GHSR 2882/4885HTR6 18/4885AKR1B1 1742/4885 |
| US-20110118280-A1 | INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | IDO2, IDO1, TPH2 | GHSR 2882/4885HTR6 18/4885AKR1B1 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.